Expertise in
2
conditions

Dr. Peter Jenkin

Dermatology
2 Pillsbury St # 501, 
Concord, NH 
Offers Telehealth
Expertise in
2
conditions
2 Pillsbury St # 501, 
Concord, NH 

Overview

Peter Jenkin is a Dermatologist practicing medicine in Concord, New Hampshire.

Dr. Jenkin is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Psoriasis, Plaque Psoriasis, Sunburn, and Contact Dermatitis.

He is actively involved in clinical research, participating in 13 clinical trials.

Specialties

Dermatology

Licenses

Dermatology in WA

Hospital Affiliations

Concord Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

2 Pillsbury St # 501, Concord, NH 03301
Other Locations
87 Mcgregor St # 2100, Manchester, NH 03102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase IIb Clinical Trial (PLANTCOAT-IIb) to Evaluate the Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase IIb Clinical Trial (PLANTCOAT-IIb) to Evaluate the Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris
Enrollment Status: Completed
Publish Date: March 25, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials
Similar Doctors
Expertise in
9
conditions
Dr. Maryanne Senna
Dermatology
Expertise in
9
conditions
Dr. Maryanne Senna
Dermatology

Office

67 S Bedford St Ste 100E, 
Burlington, MA 
 (36.5 miles away)
781-744-8443
Languages Spoken:
English
See accepted insurances

Maryanne Senna is a Dermatologist practicing medicine in Burlington, Massachusetts. Dr. Senna is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Autosomal Recessive Hypotrichosis, Alopecia Areata, Graham-Little-Piccardi-Lassueur Syndrome, and Alopecia Totalis.

Expertise in
26
conditions
Dr. Michael Chapman
Dermatology
Expertise in
26
conditions
Dr. Michael Chapman
Dermatology
18 Old Etna Rd, 
Lebanon, NH 
 (60.0 miles away)
603-650-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Chapman is a Dermatologist practicing medicine in Lebanon, New Hampshire. Dr. Chapman is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Actinic Keratosis, Melanoma, Pyoderma Gangrenosum, Squamous Cell Skin Carcinoma, and Penectomy.

Expertise in
25
conditions
Dr. Joi Carter
Dermatology
Expertise in
25
conditions
Dr. Joi Carter
Dermatology

D-H Dermatology

18 Old Etna Rd, 
Lebanon, NH 
 (60.0 miles away)
603-650-3100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joi Carter is a Dermatologist practicing medicine in Lebanon, New Hampshire. Dr. Carter is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Basal Cell Skin Cancer, and Pyoderma Gangrenosum.

Frequently Asked Questions about Dr. Peter Jenkin

How do I make an appointment with Dr. Peter Jenkin?

You can book an appointment with Dr. Peter Jenkin by calling their office at 603-626-7546. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peter Jenkin a top-rated expert for Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peter Jenkin is classified as an Advanced expert for Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peter Jenkin specialize in?

While Dr. Peter Jenkin is a Dermatology, they have specific expertise in Psoriasis, Plaque Psoriasis, and Sunburn. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Peter Jenkin accept my insurance?

Dr. Peter Jenkin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 603-626-7546 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jenkin's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile